All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck (Aplus)
A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
This PHASE2 trial investigates Adenoid Cystic Carcinoma of the Head and Neck and is currently ongoing. Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Mar 2021 — Jul 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
For direct contact, visit the study record on ClinicalTrials.gov .